aleniglipron or placebo
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity, Overweight, or Chronic Weight Management
Conditions
Obesity, Overweight, or Chronic Weight Management
Trial Timeline
Aug 15, 2025 → Oct 1, 2026
NCT ID
NCT07169942About aleniglipron or placebo
aleniglipron or placebo is a phase 2 stage product being developed by Structure Therapeutics for Obesity, Overweight, or Chronic Weight Management. The current trial status is active. This product is registered under clinical trial identifier NCT07169942. Target conditions include Obesity, Overweight, or Chronic Weight Management.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07169942 | Phase 2 | Active |
Competing Products
20 competing products in Obesity, Overweight, or Chronic Weight Management
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| exenatide + Placebo | Eli Lilly | Approved | 85 |
| Brenipatide | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |
Other Products from Structure Therapeutics
aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placeboPhase 2
47
Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + AleniglipronPhase 2
47
Aleniglipron + PlaceboPhase 2
47
GSBR-1290 + PlaceboPhase 1/2
36
GSBR-1290 (Capsule/Tablet) + GSBR-1290 + Placebo + Placebo (Capsule/Tablet)Phase 1
28